

## SYNTHESIS OF 17 $\alpha$ -AMINO-5 $\alpha$ -ANDROST-2-ENE FROM EPIANDROSTERONE

M. I. Merlani,<sup>1</sup> L. Sh. Amiranashvili,<sup>1</sup> E. P. Kemertelidze,<sup>1</sup>  
K. Papadopoulos,<sup>2</sup> and E. Yannakopulu<sup>2</sup>


UDC 547.92

*17 $\alpha$ -Amino-5 $\alpha$ -androst-2-ene was synthesized from epiandrosterone via formation of the tosylate followed by nucleophilic substitution by azide and reduction with LiAlH<sub>4</sub>. The structures of the products were proved by NMR and IR spectroscopy and mass spectrometry.*

**Key words:** aminosteroids, synthesis.

Steroidal compounds with NH<sub>2</sub>-, N-alkyl-, N-alkyloxy-, and N,N'-dialkyl-substituents in the C-17 position exhibit a broad spectrum of biological activity [1-5]. Among these compounds, amines of the 5 $\alpha$ -androstane series are also encountered. However, the biological activity of 17-amino-5 $\alpha$ -androst-2-ene and its derivatives has not been reported.

We have previously reported the preparation of a mixture of epimers of 17 $\beta$ - and 17 $\alpha$ -amino-5 $\alpha$ -androst-2-ene as intermediates in the synthesis of 17 $\beta$ -amino-5 $\alpha$ -androstane, a compound known to have anti-inflammatory and fungicidal activity [1]. Because crystallization of the mixture of epimers formed upon reduction of 17-hydroxyimino-5 $\alpha$ -androst-2-ene or 17 $\beta$ -formamido-5 $\alpha$ -androst-2-ene could isolate only the 17 $\beta$ -epimer in 60% yield, we developed a scheme for preparing 17 $\alpha$ -amino-5 $\alpha$ -androst-2-ene (**1**) using epiandrosterone that provides for the stereoselective synthesis of this epimer (Scheme 1).



Scheme 1. Synthesis of 17 $\alpha$ -amino-5 $\alpha$ -androst-2-ene from epiandrosterone.

Epiandrosterone (**2**) was transformed to 5 $\alpha$ -androst-2-ene-17-one (**3**) by the previously described method [6]. Ketone (**3**) was reduced using NaBH<sub>4</sub> in CH<sub>3</sub>OH to give stereospecifically 17 $\beta$ -hydroxy-5 $\alpha$ -androst-2-ene (**4**), reaction of which with *p*-toluenesulfonyl chloride in anhydrous pyridine gave 17 $\beta$ -(4-methylphenylsulfonyloxy)-5 $\alpha$ -androst-2-ene (**5**). We used the Streitweiser—Shaeffer method, which provides for nucleophilic substitution of the 17 $\beta$ -tosyloxy group by azide through an S<sub>N</sub>2

1) I. G. Kutateladze Institute of Pharmaceutical Chemistry, Academy of Sciences of Georgia, Tbilisi, 0159, fax (99532) 25 00 26, e-mail: maiamer@mail.ru; 2) Institute of Physical Chemistry, National Scientific Research Center Demokritos, Athens, Greece. Translated from *Khimiya Prirodnykh Soedinenii*, No. 3, pp. 257-258, May-June, 2006. Original article submitted March 2, 2006.

mechanism, to invert the configuration at C-17 [7]. This method was modified by carrying out the substitution reaction using  $\text{NaN}_3$  in DMF containing water (10%) at 105–110°C instead of *N*-methyl-2-pyrrolidone at 150°C. This formed over 48 h an oily mixture, chromatography of which over a silica-gel column isolated 17 $\alpha$ -azido-5 $\alpha$ -androst-2-ene (**6**) in 80% yield. Then reduction of azide (**6**) by an excess of  $\text{LiAlH}_4$  in THF led to the target 17 $\alpha$ -amino-5 $\alpha$ -androst-2-ene (**1**) in 80% yield. Using  $\text{LiAlH}_4$  to reduce the azide gives selective reduction that does not involve the C2–C3 double bond.

Thus, we performed a stereoselective transformation of **2** into **1** using a modified Streitweiser—Schaeffer method.

The structures of the synthesized compounds were confirmed by NMR and IR spectroscopy and mass spectrometry. The IR spectra exhibit characteristic absorption bands for the functional groups. Strong absorptions at 1372 and 1182  $\text{cm}^{-1}$  in **5** were assigned to tosyl  $\text{SO}_2$  stretching vibrations; at 2098  $\text{cm}^{-1}$ , to the azide of **6**. The  $\text{NH}_2$  stretches of **1** appeared near 3459  $\text{cm}^{-1}$ .

The PMR spectra of **1**, **5**, and **6** contained signals for C-10 and C-13 methyls as singlets with chemical shifts in the range  $\delta$  0.74–0.88 ppm. A doublet at  $\delta$  3.33–3.55 ppm with SSCC  $J = 6.2$  Hz corresponds to the 17 $\beta$ -proton in **6** and **1**. Signals for vicinal protons of the C2–C3 double bond of **1**, **5**, and **6** appeared as a distorted triplet at  $\delta$  5.59 ppm with SSCC  $J = 6.8$  Hz.

The  $^{13}\text{C}$  NMR spectra of **1**, **5**, and **6** had signals for C-18 and C-19 at  $\delta$  11.67–11.89 and 14.07–20.28 ppm, respectively; for the C=C bond of **1**, **5**, and **6**, at  $\delta$  125.8 ppm; for tosylate C–O of **5**, at  $\delta$  90.04 ppm; for C– $\text{N}_3$  of **6**, at  $\delta$  71.64 ppm; and for C– $\text{NH}_2$  of **1**, at  $\delta$  60.11 ppm.

The mass spectra of **1**, **5**, and **6** exhibited peaks for the molecular ions corresponding to the molecular weights of these compounds at 274  $[\text{M} + 1]^+$ , 428  $[\text{M}]^+$ , and 300  $[\text{M} + 1]^+$ , respectively.

The biological activity of **1** and its 17 $\beta$ -epimer is being studied.

## EXPERIMENTAL

Melting points were determined on a Gallenkamp block and are uncorrected. IR spectra were recorded on a Magna-IR spectrometer 550 in KBr disks. Mass spectra were recorded in a Finnigan AQA Navigator instrument (EI, 70 eV). NMR spectra were obtained on a Bruker AC 500 instrument (500 MHz working frequency for  $^1\text{H}$  and 125 MHz for  $^{13}\text{C}$ ). Chemical shifts of protons are given on the  $\delta$  (ppm) scale with TMS internal standard and  $\text{DMSO-d}_6$  and  $\text{CDCl}_3$  solvents. Elemental analyses were found on a Perkin—Elmer CHN 2004. Analyses of all compounds corresponded with those calculated. The course of reactions and purity of products were monitored by TLC on Silufol 254 plates (Kavalier, Czech Rep.) using  $\text{CHCl}_3:\text{CH}_3\text{OH}$  (15:1). Spots were developed by spraying with phosphomolybdic acid (10%) in ethanol and subsequent heating.

**17 $\beta$ -Hydroxy-5 $\alpha$ -androst-2-ene (4)**. A solution of **3** (2 g, 7.3 mmol) in  $\text{CH}_3\text{OH}$  (20 mL) at 0°C was treated in portions with  $\text{NaBH}_4$  (0.4 g, 10.5 mmol), stirred at 20°C for 1 h, treated with acetic acid (2 mL), and poured into water (100 mL). The precipitate was filtered off and washed with water. Recrystallization from  $\text{CH}_3\text{OH}$  afforded **4** (1.81 g, 90%), mp 161–162°C (lit. [8] mp 163°C), IR spectrum ( $\nu$ ,  $\text{cm}^{-1}$ ): 3455 (OH).

**17 $\beta$ -(4-Methylphenylsulfonyloxy)-5 $\alpha$ -androst-2-ene (5)**. A solution of **4** (1 g, 3.64 mmol) in freshly distilled pyridine (20 mL) at 0°C was treated in portions with *p*-toluenesulfonyl chloride (1.4 g, 7.28 mmol), held at 0°C for 48 h, and poured into icewater (100 mL). The precipitate was filtered off and washed with water. Recrystallization from benzene:hexane (1:4) afforded **5** (1.42 g, 85%), mp 96–98°C. IR spectrum ( $\nu$ ,  $\text{cm}^{-1}$ ): 1372 and 1182 ( $\text{SO}_2$ ). Mass spectrum ( $m/z$ ,  $I_{\text{rel}}$ , %): 482 (5)  $[\text{M}]^+$ , 257 (100).

PMR spectrum ( $\delta$ , ppm, J/Hz): 0.74 (3H, s,  $\text{CH}_3$ -18), 0.81 (3H, s,  $\text{CH}_3$ -19), 2.46 (3H, s,  $\text{CH}_3$ -OTs), 4.30 (1H, dd,  $J = 9.0, 7.7$ , H-17 $\alpha$ ), 5.59 (2H, dist. t,  $J = 6.8$ , H-2, H-3), 7.33 (2H, d,  $J = 8.2$ , OTs-17), 7.80 (2H, d,  $J = 8.2$ , OTs-17).

$^{13}\text{C}$  NMR spectrum ( $\delta$ , ppm): 11.89 (C-18), 20.28 (C-19), 23.21 ( $\text{CH}_3$ -OTs), 90.04 (C-17), 125.8 (C-2, C-3), 127.80, 129.60, 134.54, and 144.55 (C-arom.).

**17 $\alpha$ -Azido-5 $\alpha$ -androst-2-ene (6)**. A mixture of **5** (1.5 g, 3.49 mmol),  $\text{NaN}_3$  (1.5 g, 23.8 mmol), DMF (30 mL), and water (3 mL) was heated at 105–110°C for 48 h, cooled to 20°C, and poured into icewater (100 mL). The resulting oily product was chromatographed over a column (silica gel L 100/160, eluent petroleum ether:ethylacetate, 50:1) to isolate **6**, (0.83 g, 80%), mp 58–60°C. IR spectrum ( $\nu$ ,  $\text{cm}^{-1}$ ): 2098 ( $\text{N}_3$ ). Mass spectrum ( $m/z$ ,  $I_{\text{rel}}$ , %): 300 (5)  $[\text{M} + 1]^+$ , 272 (100).

PMR spectrum ( $\delta$ , ppm, J/Hz): 0.76 (3H, s,  $\text{CH}_3$ -18), 0.87 (3H, s,  $\text{CH}_3$ -19), 3.55 (1H, d,  $J = 6.87$ , H-17 $\beta$ ), 5.59 (2H, dist. t,  $J = 6.8$ , H-2, H-3).  $^{13}\text{C}$  NMR spectrum ( $\delta$ , ppm): 11.67 (C-18), 17.71 (C-19), 71.64 (C-17), 125.8 (C-2, C-3).

**17 $\alpha$ -Amino-5 $\alpha$ -androst-2-ene (1)**. A suspension of  $\text{LiAlH}_4$  (1.5 g, 39.47 mmol) in THF (100 mL) at 20°C was treated

with **6** (1.5 g, 5.0 mmol) in THF (20 mL) and boiled for 6 h. The excess of  $\text{LiAlH}_4$  was destroyed by adding water (1.5 mL), aqueous NaOH (1.5 mL, 15%), and water again (4.5 mL). The reaction mixture was filtered. The precipitate was washed with THF ( $3 \times 30$  mL). The mother liquor was acidified with HCl until the pH was 2. The solvent was removed in vacuo. The solid dissolved with heating in water (200 mL). The solution was filtered. The precipitate that formed when the mother liquor was made basic (NaOH to pH 8) was separated by filtration. Crystallization from benzene:hexane (1:2) afforded **1** (1.09 g, 80%), mp 138-140°C. IR spectrum ( $\nu$ ,  $\text{cm}^{-1}$ ): 3459 (NH). Mass spectrum ( $m/z$ ,  $I_{\text{rel}}$ , %): 274 (15)  $[\text{M} + 1]^+$ , 257 (100).

PMR spectrum ( $\delta$ , ppm, J/Hz): 0.84 (3H, s,  $\text{CH}_3$ -18), 0.88 (3H, s,  $\text{CH}_3$ -19), 3.33 (1H, br.d,  $J = 6.2$ , H-17 $\beta$ ), 5.59 (2H, dist. t,  $J = 6.8$ , H-2, H-3).  $^{13}\text{C}$  NMR spectrum ( $\delta$ , ppm): 11.73 (C-18), 14.07 (C-19), 60.11 (C-17), 125.83 (C-2, C-3).

## ACKNOWLEDGMENT

The work was supported by grant NATO FEL.RIG 987703. We thank Dr. Leondios Leondiadis, Head of the Mass Spectrometry Laboratory, National Scientific Research Center Demokritos, for his work.

## REFERENCES

1. J. C. Babcock, U.S. Pat. No. 3,009,925 (1961); *Chem. Abstr.*, **56**, P10234f (1962).
2. Y. Ye, Y. Huang, Z. Wang, S. Chen, and Y. Tian, *Steroids*, **58**, 35 (1993).
3. P. Kaspar and H. Witzel, *J. Steroid Biochem.*, **23**, 259 (1985).
4. R. T. Blickenstaff, E. Foster, K. Gerzon, and P. Young, *Steroids*, **46**, 889 (1985).
5. I. Vincze, L. Hackler, Z. Szendi, and G. Schneider, *Steroids*, **61**, 697 (1996).
6. M. I. Merlani, M. G. Davitishvili, N. Sh. Nadaraia, M. I. Sikharulizde, and K. Papadopulos, *Chem. Nat. Comp.*, **40**, 2, 144 (2004).
7. M. Davis, E. W. Parnell, and D. Warburton, *J. Chem. Soc. C*, 1698 (1966).
8. M. M. Janot, K. H. Qui, and R. Goutarel, *Bull. Soc. Chim. Fr.*, 1640 (1960).